PROTECTED TAVR – Impact on Clinical Practice - Webinar

Watch the replay of this webinar if you want to understand interpreting PTAVR in a practical manner to reflect clinical practice, to address the role of CEP in Lifetime Patient Management for TAVI and to focus on the periprocedural benefits of Sentinel.

[RNHD-sedk]

This is the problem with Industry-funded The primary endpoint was clearly negative can´t propose a potential benefit ( as they did in the conclusion of the paper published in NEJM) based on a secondary endpoint. That is just wrong